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Abstract 
AIM: To assess the frequency of carotid artery disease (CAD) and lower extremities artery disease (LEAD) in 
patients with chronic obstructive pulmonary disease (COPD) and their relation to the severity of airflow limitation 
and the level of C-reactive protein (CRP).  
METHODS: We performed a cross-sectional study including 60 patients with COPD (52 male, 8 female), aged 40 
to 80 years, initially diagnosed according to the actual criteria. Also, 30 subjects in whom COPD was excluded, 
matched to COPD patients by sex, age, body mass index and smoking status, served as controls. All study 
subjects completed questionnaire and underwent pulmonary evaluation (dyspnea severity assessment, baseline 
and post-bronchodilator spirometry, gas analyses, and chest X-ray), angiological evaluation by Doppler 
ultrasonography and measurement of serum CRP level.  
RESULTS: We found a statistically significant difference between the frequency of carotid plaques in COPD 
patients as compared to their frequency in controls (65% vs 30%; P = 0.002). The mean value of intima-media 
thickness (IMT) in COPD patients with CAD was significantly higher than its mean value in controls (0.8 ± 0.2 vs. 
0.7 ± 0.2; P = 0.049). IMT value in COPD patients with CAD was significantly related to the degree of airflow 
limitation, i.e. to the degree of FEV1 decline (P = 0.000), as well as to the serum CRP level (P = 0.001). We found 
a statistically significant difference between the frequency of COPD patients with LEAD as compared to the 
frequency of LEAD in controls (78.3% vs 43.3%; P = 0.001). According to the Fontaine classification, COPD 
patients with LEAD were categorized in the stages I, IIA and IIB (53.3%, 30% and 16.7%, respectively), whereas 
all controls with LEAD were categorized in the Fontaine stage I. Among COPD patients with LEAD there was 
significant association between disease severity and clinical manifestations due to the vascular changes (P = 
0.001) and serum CRP level (P = 0.001).  
CONCLUSION: Our findings suggest higher prevalence and higher severity of vascular changes in COPD 
patients as compared to their prevalence and severity in non-COPD subjects. Prevalence and severity of vascular 
changes in COPD patients were significantly related to the severity of airflow limitation and serum CRP levels. 
 
 
 
Introduction 
 
COPD is a systemic disease with many 
comorbidities like: cardiovascular disease (CVD), 
anemia, polycythemia, malnutrition, muscle disorder, 
osteoporosis, metabolic syndrome, diabetes, 
gastroesophageal reflux, anxiety, depression, 
hormonal imbalance, infections, lung cancer, 
thrombosis [1], [2], [3], [4], [5]. The major cause for 
hospitalisation and mortality in COPD patients are 
CVD: heart failure, ischemic heart disease, 
arrhythmias, peripheral artery disease (PAD) and 
hypertension [1], [3], [4], [6], [7], [8], [9].  
Cigarette smoking is a common risk factor for 
both diseases, but there are other predictors such as 
inflammation, oxidative stress, hypoxia, endothelial 
dysfunction, prosthesis/antiprotease imbalance etc. 
[10], [11]. COPD is characterised by chronic, low-
grade, systemic inflammation that leads to 
atherosclerosis [12]. In a review of 14 relevant 
studies, Gan et al. demonstrated that levels of 
systemic inflammatory markers are increased in 
patients with COPD compared to smokers without 
COPD [10], [13]. Elevated C-reactive protein (CRP) as 
a marker of systemic inflammation is present in stable 
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COPD, as well as in COPD exacerbations [6]. The 
prevalence of PAD in COPD patients is wide-ranging. 
Lyn et al. reported the prevalence of asymptomatic 
PAD in Taiwan of 8.4%, Pecci in a Hispanic study of 
36.8%, Pizzaro in a German study of 80% and 
Castagna in a French study of 81%. The common 
conclusion in all these studies is that patients with 
COPD and PAD, have worse pulmonary function [14], 
[15], [16], [17], [18], [19]. 
We aimed to assess the frequency of carotid 
artery disease (CAD) and lower extremities artery 
disease (LEAD) in patients with chronic obstructive 
pulmonary disease (COPD) and their relation to the 
severity of airflow limitation and the level of C-reactive 
protein (CRP). 
 
 
Material and Methods 
 
Study design and setting 
A cross-sectional study aimed at comparison 
of frequency and severity of carotid and lower limb 
arteries changes in initially diagnosed COPD patients 
and non-COPD controls was performed at the 
General Hospital "8-th September", Skopje, 
Macedonia in the period January – May 2018. The 
study was approved by the Ethics Committee of the 
Medical Faculty at University Ss. "Cyril and 
Methodius” of Skopje, Skopje, Republic of Macedonia 
(03-2237/5/21.05.2018). 
 
Study subjects 
The study population included 60 patients 
with COPD initially diagnosed according to the actual 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) criteria and 30 subjects without COPD 
matched to the COPD group by sex, age, body mass 
index (BMI), and smoking status. All enrolled subjects 
gave their written informed consent before entering 
the study.  
Inclusion criteria for COPD group were: both 
genders, age 40-80 years, newly diagnosed COPD 
according to the actual GOLD (Global Initiative for 
Chronic Obstructive Lung Disease) criteria, and 
history of current or former smoking (equal or more 
than 10 pack-years).  
Exclusion criteria for COPD group were: age 
less than 40 years and more than 80 years, BMI 
higher than 35, other chronic respiratory diseases 
(asthma, bronchiectasis, active tuberculosis, 
sarcoidosis, lung carcinoma, pulmonary fibrosis, sleep 
apnea syndrome), other chronic diseases (valvular 
and congenital heart disease, left ventricular 
hypertrophy, diabetes mellitus, hepatic and renal 
failure, anaemia, electrolyte imbalance, and 
immunosuppressive therapy), contraindication for 
spirometry, and patients who did not agree to 
participate in the study.  
Inclusion criteria for the non-COPD group 
were: Age 40-80 years, current or former smoking 
(equal or more than 10 pack-years), BMI higher than 
35, no pulmonary abnormalities, normal spirometric 
finding, clinically stable condition, and signed consent 
for participation in the study.  
 
Study protocol 
All study subjects completed questionnaire, 
as well as underwent a pulmonary and angiological 
evaluation and measurements of serum CRP.  
 
Questionnaire 
The questionnaire included questions on 
demographics (sex, age, weight and height, working 
history, socio-economic status), smoking history, 
respiratory and other symptoms in the last 12 months, 
as well as medical history and medication use. 
The BMI as a measure of body fat based on 
height and weight that applies to adult population was 
determined in all study subjects by computed 
calculation using BMI calculator [20].  
Classification of smoking status was done by 
the World Health Organization (WHO) 
recommendations [21].  
Respiratory symptoms in the last 12 months 
(cough, phlegm, dyspnea, wheezing, and chest 
tightness) were documented using the European 
Community for Coal and Steel questionnaire (ECCS-
87), and the European Community Respiratory Health 
Survey (ECRHS) questionnaire [22], [23]. 
 
Pulmonary evaluation 
The pulmonary evaluation included: dyspnea 
severity assessment, baseline and post-
bronchodilator spirometry, arterial gas analysis, and 
chest X-ray.  
Dyspnea severity was assessed by the British 
Medical Council Dyspnea Scale [24].  
The baseline spirometry, including measures 
of forced vital capacity (FVC), forced expiratory 
volume in one second (FEV1), FEV1/FVC, and 
maximal expiratory flow at 75%, 50%, 25%, and 25-
75% of FVC (MEF75, MEF50, MEF25, and MEF25-75, 
respectively), was performed in all subjects using 
electronic spirometer Spirobank G USB Spirometer 
(Medical International Research, Roma, Italy) with 
recording the best result from three measurements 
the values of FEV1 of which were within 5% of each 
other. The results of spirometry were expressed as 
percentages of the predicted values according to the 
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actual recommendations of the European Respiratory 
Society (ERS) and ATS [25].  
Bronchodilator test was performed by 
spirometric measurements before and 20 minutes 
after administration of 400 g salbutamol by metered 
dose inhaler through the spacer. Post-bronchodilator 
value of the FEV1/FVC ratio less than 0.70 indicated 
persistent airflow limitation [25].  
According to the actual GOLD 
recommendations, COPD was considered by finding 
of a post-bronchodilator FEV1/FVC ratio less than 0.70 
in symptomatic subjects (dyspnea, chronic cough 
and/or sputum production) with a history of exposure 
to risk factors for the diseases (noxious particles and 
gases). In addition, according to the FEV1 value, 
airflow limitation in the subjects with COPD, i.e. 
severity of the disease, was classified as mild (FEV1 
value higher than 80% of the predicted value), 
moderate (FEV1 value higher than 50% but lower than 
80% of the predicted value), severe (FEV1 value 
higher than 30% but lower than 50% of the predicted 
value), and very severe (FEV1 value lower than 30% 
of the predicted value) [1].  
The gas analysis was performed with 
SIEMENS RAPIDPOINT 405 System (Siemens 
Healthineers, Australia).  
 
Angiological evaluation 
Doppler ultrasonography of carotid arteries 
was performed with high-resolution General Electric 
Vivid 7 (GE Healthcare, Milwaukee, USA), B mode 
ultrasonography, 5-10MHz multifrequency linear 
probe. Carotid intima-media thickness (IMT), as an 
indicator of subclinical atherosclerosis, was measured 
in three points: at the site of the largest thickening, at 
the proximal and distal point. The mean value in these 
three points was calculated for each carotid artery, 
and the highest value was taken for IMT. Lesions with 
IMT greater than 1.2 mm were defined as 
atheromatous plaques [26].  
Doppler ultrasonography of lower limb arteries 
was performed with the same General Electric Vivid 7 
ultrasound system receiving information about the 
localisation, extensiveness and severity of vascular 
lesions [27]. LEAD may be asymptomatic or 
symptomatic. Fontaine classification is a classification 
based on clinical symptoms of the disease, which 
includes five stages: I, IIa, IIb, III, IV. Stage I refers to 
asymptomatic or subtle symptoms such as 
paraesthesia, stage IIa to intermittent claudication 
after walking more than 200 m, stage IIb to 
claudication at walking less than 200 m, stage III to 
resting pain, especially during the night, and stage IV 
to ischemic ulceration or gangrene [28]. 
 
 
Serum CRP measurements 
All study participants underwent blood 
sampling and measuring of CRP in serum by latex-
enhanced immunonephelometric assay (ABX Pentra 
CRP CP, HORIBA GROUP, Montpellier, France), 
reference value 0-10mg/L.  
 
Statistical analysis 
Statistical analysis was done using the SPSS 
Statistics 17 software package (SPSS. Inc., Chicago, 
IL, USA). The results of the tests were usually 
expressed with numerical values, so the comparison 
between them was performed using a correlation with 
the Pearson Correlation test. To test hypotheses 
involving multiple samples, a standard Student t-test 
for two or more samples was used. The Mann-
Whitney U-test was used to test two independent 
samples. In the case of more than two samples, a 
Kruskal-Wallis H test of K-independent samples was 
used, which is a one-way analysis of the variants of 
independent samples (one-way ANOVA on ranks). 
The level of statistical significance was set at P value 
less than 0.05. 
 
 
Results 
 
Demographic and other characteristics of the 
study subjects are given in Table 1. The two groups 
were similar regarding the sex and age distribution of 
the included subjects, as well as regarding their 
smoking status and mean BMI. The mean values of 
spirometric parameters (FVC, FEV1 and FEV1/FVC 
ratio) were significantly lower in COPD patients than 
in non-COPD controls. Also, the mean value of serum 
CRP was significantly higher in COPD patients than in 
non-COPD (10.2 vs 5.9; P = 0.04), suggesting a low-
grade systemic inflammation in these patients.  
Table 1: Demographics and other characteristics of the study 
subjects 
Characteristic 
COPD patients 
(n = 60) 
Non-COPD subjects 
(n = 30) 
Sex 
Males 
Females 
 
52 (86.7%) 
8 (13.3%) 
 
23 (76.7%) 
7 (23.3%) 
Mean age (years) 
Males 
Females 
 
65.9 ± 7.5 
67.9 ± 6.1 
 
64.8 ± 8.6 
66.7 ± 7.8 
Smoking status 
Active smokers 
Former smokers 
Pack-year smoked 
 
35 (58.3%) 
25 (41.7%) 
66.1 ± 25.8 
 
18 (60%) 
12 (40%) 
67.4 ± 25.5 
Mean BMI value 25.8 ± 4.9 24.9 ± 2.1 
Mean baseline values  
of spirometric parameters 
FVC (% pred) 
FEV1 (% pred) 
FEV1/FVC ratio 
 
 
78.8 ± 12.3 
47.5 ± 17.9 
0.6 ± 0.07 
 
 
115.2 ± 16.8 
92.3 ± 14.7 
0.8 ± 0.05 
Level of serum CRP 
< 3,14 mg/L 
3,14 - 10mg/L 
> 10mg/L 
 
10 (16.7%) 
27 (45%) 
23 (38.3%) 
 
15 (50%) 
10 (33.3%) 
5 (16.7%) 
COPD: chronic obstructive pulmonary disease; BMI: body mass index; FVC: forced vital 
capacity; FEV1: forced expiratory volume in one second; %pred: percentage of the 
predicted value; CRP: C-reactive protein; mg: milligram; L: litre. 
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According to the severity of airflow limitation, 
i.e. to the post-bronchodilator value of FEV1, COPD 
patients were categorised in four stages: mild, 
moderate, severe and very severe COPD.  
Table 2: Distribution of the COPD patients by degree of airflow 
limitation 
COPD severity 
COPD patients 
(n = 60) 
GOLD 1 - mild 
(FEV1 ≥ 80% pred) 
4 (6.7%) 
GOLD 2 – moderate 
(FEV1 = 50% – 79% pred) 
21 (35%) 
GOLD 3 – severe 
(FEV1 = 30% – 49% pred) 
22 (36.7%) 
GOLD 4 – very severe 
(FEV1 < 30% pred) 
13 (21.7%) 
COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic 
Obstructive Lung Disease; FEV1: forced expiratory volume in one second; %pred: 
percentage of the predicted value.  
 
Doppler-ultrasonography of carotid arteries 
detected a statistically significant difference between 
the frequency of carotid plaques in COPD patients as 
compared to their frequency in controls (65% vs 30%; 
P = 0.002). Distribution of COPD patients with carotid 
plaques by the degree of airflow limitation is 
presented in Table 3. 
Table 3: Distribution of COPD patients with carotid plaques by 
the degree of airflow limitation 
COPD patients 
(n = 60) 
Plaques without 
stenosis 
Plaques with stenosis 
up to 40% 
Plaques with stenosis 
40-60% 
GOLD 1 
(n = 4) 
0 (0%) 0 (0%) 0 (0%) 
GOLD 2 
(n = 21) 
7 (33.3%) 2 (9.5%) 1 (4.7%) 
GOLD 3 
(n = 22) 
11 (50%) 2 (9%) 5 (22.7%) 
GOLD 4 
(n = 13) 
3 (23%) 5 (38.4%) 3 (23%) 
COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic 
Obstructive Lung Disease. 
 
The mean value of IMT in COPD patients with 
detected carotid plaques was 0.8 ± 0.2, whereas its 
mean value in controls was 0.7 ± 0.2 (P = 0.049). IMT 
value in COPD patients with CAD was significantly 
related to the degree of airflow limitation, i.e. to the 
degree of FEV1 decline (P = 0.000), as well as to the 
serum CRP level (P = 0.001).  
We found a statistically significant difference 
between the frequency of LEAD in COPD patients as 
compared to their frequency in controls (78.3% vs 
43.3%; P = 0.001). The distribution of COPD patients 
with LEAD by the degree of airflow limitation is 
presented in Table 4.  
Table 4: Distribution of COPD patients with LEAD by the 
degree of airflow limitation 
COPD patients 
(n = 60) 
Initial 
atherosclerotic 
plaques without 
stenosis 
Diffuse 
atherosclerotic 
plaques without 
stenosis 
Plaques with 
stenosis up to 
40% 
Plaques with 
stenosis 40-60% 
GOLD 1 
(n = 4) 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
GOLD 2 
(n = 21) 
 
5 (23.8%) 3 (14.3%) 3 (14.3%) 2 (9,5%) 
GOLD 3 (n = 22) 
 
4 (18.2%) 7 (31.8%) 6 (27.3%) 4 (18.2%) 
GOLD 4 (n = 13) 0 (0%) 3 (23%) 5 (38.4%) 5 (38.4%) 
COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic 
Obstructive Lung Disease. 
 
According to the Fontaine classification, 
COPD patients with LEAD were categorised in the 
stages I, IIA and IIB (53.3%, 30% and 16.7%, 
respectively), whereas all controls with LEAD were 
categorised in the Fontaine stage I.  
Among COPD patients with LEAD, there was 
a significant association between disease severity, i.e. 
FEV1 value, and clinical manifestations due to the 
vascular changes (P = 0.001). The relation between 
clinical manifestations of LEAD and serum CRP level 
was also statistically significant (P = 0.001).  
 
 
Discussion 
 
Vascular changes are one of the 
cardiovascular complications of COPD, probably due 
to the chronic, low-grade, systemic inflammation that 
leads to atherosclerosis in carotid and other arteries 
[29]. The inflammatory cascade that initially arises 
from exposure to noxious substances, mainly tobacco 
smoke, accelerates atherogenesis at all stages by 
formation, destabilisation and rupture of plaque as 
well as by platelet activation and clotting that lead to 
atheroma formation and atherothrombosis [18]. 
Nevertheless, the association between COPD and 
vascular comorbidities, i.e. CAD and LEAD, is still 
poorly understood [30]. 
Our study aimed to assess the frequency of 
CAD and LEAD in patients with initially diagnosed 
COPD and their relation to the severity of airflow 
limitation and the serum level of CRP. We performed 
a cross-sectional study, including 60 patients with 
COPD (52 male, 8 female), aged 40 to 80 years, 
diagnosed according to the actual criteria. Also, 30 
subjects in whom COPD was excluded, matched to 
COPD patients by sex, age, BMI, and smoking status, 
served as controls. Airflow limitation in over half of the 
COPD patients were classified as severe and very 
severe, suggesting the delayed diagnosis, as well as 
the late onset of appropriate treatment of the disease.  
Doppler-ultrasonography of carotid arteries 
detected a statistically significant difference between 
the frequency of carotid plaques in COPD patients as 
compared to their frequency in controls. Also, the 
mean value of IMT in COPD patients with detected 
carotid plaques was significantly higher as compared 
to its mean value in controls with detected carotid 
plaques. IMT value in COPD patients with CAD was 
significantly related to the COPD severity, i.e. to the 
post-bronchodilator value of FEV1, as well as to the 
serum CRP level.  
In the study on subclinical cardiovascular 
changes in COPD patients, Sadeka et al. found that 
patients with COPD had a higher frequency of carotid 
plaques and the higher mean value of IMT compared 
to non-COPD controls, but they did not find a 
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significant association between these findings and the 
severity of COPD [31]. On the other side, the MESA 
Lung Study on the link between subclinical 
atherosclerosis and emphysema confirmed the 
presence of higher mean IMT value in smokers 
compared to non-smokers [32]. Furthermore, unlike 
the results of the Sadeka’s study, Kim et al., reported 
results similar to our findings, i.e. significantly higher 
frequency of CAD in COPD patients than in non-
COPD controls and its significant relation to COPD 
severity and serum level of CRP as a marker of 
systemic inflammation [31], [33].  
We found a statistically significant difference 
between the frequency of LEAD in COPD patients as 
compared to their frequency in controls. According to 
the Fontaine classification, COPD patients with LEAD 
were categorised in the stages I, IIA and IIB, whereas 
all controls with LEAD were categorised in the 
Fontaine stage I suggesting more expressed clinical 
manifestations of LEAD in COPD patients as 
compared to their manifestations in controls. Among 
COPD patients with LEAD, there was a significant 
association between disease severity, i.e. the post-
bronchodilator FEV1 value, and clinical manifestations 
due to the vascular changes. The relation between 
clinical manifestations of LEAD and serum CRP level 
was also statistically significant. 
Similarly to our findings, in a Spanish cross-
sectional study, Pecci et al., found that LEAD is 
present with a high prevalence in patients with COPD 
[34]. The same, i.e. a high frequency of LEAD in 
COPD patients (80.4%), was also demonstrated by 
Pizzaro et al., [18]. On the other side, Watz et al. 
demonstrated a lower frequency of LEAD in COPD 
patients (25.3%) [35]. These differences are mainly 
due to the different methodology used for detection of 
LEAD, i.e. its diagnosis in the study performed by 
Watz et al., was based on ankle-brachial 
measurements, whereas in the studies performed by 
Pecci et al., and Pizzaro et al., the diagnosis was 
based on the colour duplex sonography of lower 
extremity arteries [18], [34], [35].  
The present study must be interpreted within 
the context of its limitations. First, a relatively small 
number of the study subjects could have certain 
implications on data obtained and its interpretation. 
Also, the unequal distribution of COPD patients by 
degree of the disease severity could have certain 
implications on data obtained and its interpretation. 
On the other hand, detection of the vascular changes 
in newly diagnosed COPD patients is the strength of 
the study. 
In conclusion, our findings suggest higher 
frequency and higher severity of vascular lesions in 
newly diagnosed COPD patients as compared to their 
prevalence and severity in non-COPD subjects. 
Frequency and severity of vascular changes in COPD 
patients were significantly related to the severity of 
airflow limitation and serum CRP levels. Our findings 
also suggest a need for early screening for vascular 
comorbidities in COPD patients to detect them and to 
obtain an integrated-care approach in the 
management of these patients.  
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